Latest Product Development News

One Click Group Limited reported a 42% increase in registered users and a 26% rise in revenue to $4.9 million in Q4 2024, while preparing to launch its new superannuation product in 2025.

Optiscan Imaging Ltd reported a productive December quarter, marked by key product developments, strategic partnerships, and a stronger cash position, setting the stage for growth in medical and veterinary imaging markets.

xReality Group Limited has reported its strongest quarter yet, with cash receipts soaring 87% year-on-year to $5.2 million, driven by robust growth in its Operator XR enterprise software and entertainment divisions.

Beonic's Q2 FY2025 results reveal steady recurring revenue growth and a significant gross margin improvement, underpinning its path to cashflow breakeven. Strategic contract wins and leadership appointments position the company for accelerated IoT adoption.

ImpediMed Limited has reported record quarterly revenue and cash receipts for Q2 FY25, alongside significant growth in reimbursement coverage and a robust sales pipeline, signaling strong momentum in its digital health platform business.

Optiscan Imaging Ltd has secured a $1.775 million R&D tax refund for FY24, more than doubling last year’s amount thanks to expanded claims on overseas research. The boost will fund ongoing development of its cutting-edge confocal laser endomicroscopy technology.

Vitrafy Life Sciences reports strong Q2 FY2025 progress, marked by a successful $35 million IPO, promising validation results in animal and human health, and strategic expansion into North America.

ResMed Inc. posted a robust second quarter for fiscal year 2025, with revenue climbing 10% to $1.3 billion and operating profit soaring 52%, driven by strong demand for sleep and breathing health products and operational efficiencies.

WhiteHawk Limited reports solid Q4 2024 results with $718K revenue and a major $2.4 million contract renewal, while advancing new partnerships and managing costs amid a modest operational cash loss.

My Rewards International Limited reports steady progress on its B2B rewards platform and the soft launch of its Klevo MasterCard, while navigating ongoing ASX suspension and securing a $15 million financing facility.

Zelira Therapeutics has secured a fourth funding tranche of US$681,000, advancing its HOPE® Autism Spectrum Disorder FDA trial process and bringing total funding to US$3.25 million. The company is progressing clinical validation and product development, including the transformation of Zenivol® into a capsule formulation.

Cycliq Group Ltd reports a robust Q2 FY2025 with a 15% rise in cash receipts to $1.92 million and strategic leadership appointments aimed at accelerating growth.